Droxidopa is a Small Molecule owned by Sumitomo Pharma, and is involved in 9 clinical trials, of which 8 were completed, and 1 is ongoing.

Droxidopa is an orally active precursor of norepinephrine and dopa decarboxylase inhibitor. Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Increased levels of norepinephrine in the central nervous system (CNS) may be beneficial to patients in a wide range of indications. Norepinephrine agonises the alpha (Alpha1 and Alpha 2) and beta adrenergic receptors.

The revenue for Droxidopa is expected to reach a total of $213m through 2031. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Droxidopa NPV Report.

Droxidopa is originated and owned by Sumitomo Pharma. H. Lundbeck is the other company associated in development or marketing of Droxidopa.

Droxidopa Overview

Droxidopa (Northera, DOPS) is a synthetic amino acid precursor of noradrenaline. It is formulated as hard gelatin capsules and granules for oral route of administration. Droxidopa is indicated for the treatment of orthostatic dizziness, lightheadedness, in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. It is also indicated for the prevention of the alleviation of vertigo, staggering, dizziness on standing up, lassitude, and weakness in hemodialytic patients with orthostatic (postural) hypotension. It was under development for the treatment of attention deficit hyperactivity disorder (ADHD), fibromyalgia, intra dialytic hypotension, chronic fatigue syndrome and orthostatic hypotension.

H. Lundbeck Overview

H. Lundbeck (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company’s products are indicated for the treatment of Alzheimer’s disease, migraine, depression, Parkinson’s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, depression, anxiety, psychosis, and epilepsy, among others. It operates production facilities in Denmark, France, Italy, and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in Italy, China, Spain, Canada, Australia, the US, and other countries. Lundbeck is headquartered in Valby, Denmark.

The company reported revenues of (Danish Krone) DKK16,299 million for the fiscal year ended December 2021 (FY2021), a decrease of 7.8% over FY2020. In FY2021, the company’s operating margin was 12.3%, compared to an operating margin of 11.3% in FY2020. In FY2021, the company recorded a net margin of 8.1%, compared to a net margin of 8.9% in FY2020. The company reported revenues of DKK4,719 million for the third quarter ended September 2022, an increase of 5.5% over the previous quarter.

Quick View – Droxidopa

Report Segments
  • Innovator (NME)
Drug Name
  • Droxidopa
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Ear Nose Throat Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.